文献速递血栓与止血

英国成人免疫性血小板减少症患者使用血小板生成素受体激动剂的真实世界研究:TRAIT研究结果

Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study.
PubMed 文献 · Br J Haematol · 2024-03-01

TRAIT为回顾性观察研究,纳入英国267例成人免疫性血小板减少症(ITP)患者,评估罗米司亭与艾曲泊帕的真实世界血小板反应及不良反应。首次TPO-RA治疗中89%患者血小板计数≥30×10⁹/L,68%≥100×10⁹/L,18%获得无治疗反应;61例(23%)转换TPO-RA,第二种TPO-RA仍可使多数患者血小板≥30×10⁹/L。

要点

  • 首次TPO-RA治疗中89%达血小板≥30×10⁹/L,68%达≥100×10⁹/L
  • 全组18%获得无治疗反应(停药3个月后血小板≥30×10⁹/L)
  • 61例(23%)转换TPO-RA,第二种TPO-RA仍可使多数患者血小板≥30×10⁹/L

核心结论

  • 两种TPO-RA的真实世界疗效与安全性特征与临床研究报告相似。
  • 无治疗反应与继发性ITP、诊断后早期启用TPO-RA、存在合并症及无既往脾切除或未使用类固醇或霉酚酸酯相关。

研究设计与样本

  • TRAIT为回顾性观察研究,纳入英国267例成人ITP患者(原发性ITP 218例,继发性ITP 49例),诊断时中位年龄48岁。
  • 112例(42%)首选艾曲泊帕,155例(58%)首选罗米司亭作为第一种TPO-RA。

主要发现

  • 首次TPO-RA治疗中89%患者血小板计数≥30×10⁹/L,68%患者≥100×10⁹/L。
  • 全组18%患者获得无治疗反应(停药3个月后血小板计数≥30×10⁹/L)。
  • 61例(23%)转换TPO-RA;从艾曲泊帕转换为罗米司亭者中23/25(92%)达到血小板≥30×10⁹/L,从罗米司亭转换为艾曲泊帕者中28/36(78%)达到血小板≥30×10⁹/L。

关键数值与推荐

  • 无治疗反应定义为停药3个月后血小板计数≥30×10⁹/L。
  • 无治疗反应与继发性ITP、诊断后早期启用TPO-RA、存在合并症及无既往脾切除或未使用类固醇或霉酚酸酯相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Few studies have reported the real-world use of both romiplostim and eltrombopag in immune thrombocytopenia (ITP). TRAIT was a retrospective observational study aimed to evaluate the platelet responses and adverse effects associated with the use of these thrombopoietin receptor agonists (TPO-RAs) in adult patients with ITP in the United Kingdom. Of 267 patients (median age at diagnosis, 48 years) with ITP (primary ITP [n = 218], secondary ITP [n = 49]) included in the study, 112 (42%) received eltrombopag and 155 (58%) received romiplostim as the first prescribed TPO-RA. A platelet count ≥30 × 109/L was achieved in 89% of patients with the first TPO-RA treatments, while 68% achieved a platelet count ≥100 × 109/L. Treatment-free response (TFR; platelet count ≥30 × 109/L, 3 months after discontinuing treatment) was achieved by 18% of the total patients. Overall, 61 patients (23%) switched TPO-RAs, most of whom achieved platelet counts ≥30 × 109/L with the second TPO-RA (23/25 who switched from eltrombopag to romiplostim [92%]; 28/36 who switched from romiplostim to eltrombopag [78%]). TFR was associated with secondary ITP, early TPO-RA initiation after diagnosis, the presence of comorbidity and no prior splenectomy or treatment with steroids or mycophenolate mofetil. Both TPO-RAs had similar efficacy and safety profiles to those reported in clinical studies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Cooper N, Scully M, Percy C, et al. Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study. Br J Haematol. 2024. PMID: 38429869. doi:10.1111/bjh.19345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。